FDA Grants SeaStar Medical's Selective Cytopheretic Device Breakthrough Device Designation for Hepatorenal SyndromeGlobeNewsWire • 10/18/23
SeaStar Medical to Present at the Dawson James Small Cap Growth Conference on October 12, 2023GlobeNewsWire • 10/05/23
SeaStar Medical Provides Regulatory Update Regarding Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device ExemptionGlobeNewsWire • 10/03/23
FDA Grants Breakthrough Device Designation to SeaStar Medical's Selective Cytopheretic Device for Cardiorenal SyndromeGlobeNewsWire • 09/29/23
SeaStar Medical to Hold Business Update Conference Call Today at 4:00 p.m. Eastern TimeGlobeNewsWire • 08/22/23
SeaStar Medical Reports Second Quarter 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • 08/14/23
SeaStar Medical to Sponsor the Critical Care Time Podcast Series Covering Vital Medical Issues for Healthcare Professionals Who Care for Critically Ill PatientsGlobeNewsWire • 06/30/23
First Patient Enrolled in SeaStar Medical's Pivotal Clinical Trial with the Selective Cytopheretic Device in Adults with Acute Kidney InjuryGlobeNewsWire • 06/20/23
SeaStar Medical Reports First Quarter 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • 05/15/23
SeaStar Medical to Present at the JMP Securities Life Sciences Conference on May 16, 2023GlobeNewsWire • 05/10/23
SeaStar Medical Reports 2022 Financial Results and Provides a Business UpdateGlobeNewsWire • 03/30/23
SeaStar Medical to Present at the Emerging Growth Virtual Conference on March 22, 2023GlobeNewsWire • 03/15/23
SeaStar Medical's Selective Cytopheretic Device to be Featured at the 5th Chronic Kidney Disease Drug Development SummitGlobeNewsWire • 02/24/23
SeaStar Medical Announces Details of the Selective Cytopheretic Device Pivotal Study in Critically ill Adults with Acute Kidney InjuryGlobeNewsWire • 02/15/23
SeaStar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney InjuryGlobeNewsWire • 02/09/23
SeaStar Medical Submits Investigational Device Exemption (IDE) Application to FDA to Study a Novel Therapy to Reduce Hyperinflammation in Adult Acute Kidney Injury PatientsGlobeNewsWire • 01/09/23
SeaStar Medical Bolsters Operational Expertise with Appointment of Thomas R. Mullen as Vice President of Operations and Product DevelopmentGlobeNewsWire • 12/02/22
SeaStar Medical's Lead Product Candidate, the Selective Cytopheretic Device (SCD), Included in Consensus Statement for Pediatric Acute Kidney Injury in First Pediatric Acute Disease Quality Initiative (ADQI) MeetingGlobeNewsWire • 11/07/22
SeaStar Medical (NASDAQ: ICU) Commences Trading on Nasdaq Capital Market and Outlines Corporate Strategy and Near-Term CatalystsGlobeNewsWire • 10/31/22